Donanemab therapy in Alzheimer's disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement - PubMed
5 hours ago
- #Alzheimer's disease
- #Biomarkers
- #Donanemab
- Donanemab therapy shows promise in treating Alzheimer's disease with mild cognitive impairment.
- The therapy leads to normalization of amyloid, tau, and plasma biomarkers.
- Cognitive improvement is observed in patients undergoing Donanemab therapy.
- The authors declare no competing financial interests or personal relationships influencing the study.